



Press communication

Lund, Sweden, 3 November 2022

This is a translation of the Swedish press release published 2022-11-03

## Neola Medical invites to presentation of the Q3-report 2022

**Neola Medical AB (publ) invites to presentation of the Q3-report of 2022, Thursday the 10th of November 2022 at 11am CET (11.00). The presentation will be held online as a video conference. The Q3-report will be published the same morning.**

Neola Medical publishes the Q3-report in the morning the 10th of November 2022. We hereby invite investors, analysts, and journalists to a combined report presentation and video conference Thursday the 10th of November 2022 at 11am CET (11.00). The report will be presented by CEO Hanna Sjostrom and CFO Christian Gyllenberg. After the presentation it will be possible for those who participate to ask questions live through the chat.

Please sign up in advance by sending an e-mail to Anna Goffhé, CEO Assistant at [anna.goffhe@neolamedical.com](mailto:anna.goffhe@neolamedical.com). After sign-up you will be invited to the video conference by receiving a link to a Microsoft Teams meeting. You can also send questions in advance to the same e-mail address.

For further questions after the presentation, contact CFO Christian Gyllenberg through below contact details.

The report and report presentation will be available at Neola Medical's website:

<https://www.neolamedical.com/investors/rapporter-och-finansiell-kalender/>

**For further information, contact**

Hanna Sjöström, CEO Neola Medical, tel: 0760-10 71 16, e-mail: [hanna.sjostrom@neolamedical.com](mailto:hanna.sjostrom@neolamedical.com)

Christian Gyllenberg, CFO Neola Medical, tel: 0727-44 50 10, e-mail: [christian.gyllenberg@neolamedical.com](mailto:christian.gyllenberg@neolamedical.com)

---

*Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants' lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at [www.neolamedical.com](http://www.neolamedical.com). The company's Certified Adviser is FNCA Sweden AB.*